Emmaus Life Sciences, Inc. (EMMA) stock
EMMAOTCPharmaceutical PreparationsFiscal year ends December 31
$0.05−0.01 (-14.38%)
Close on Oct 19, 2026Market cap $6.03MP/E –Yield –
Emmaus Life Sciences profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Emmaus Life Sciences's profit margin for the twelve months ending Jun 30, 2026 was -38.8%. For fiscal 2025 it was -60.2%, against -38.7% the year before. The highest annual figure on record is 5.8% in fiscal 2020.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -60.2% | −21.4 |
| FY2024 | Dec 31, 2024 | -38.7% | −26.1 |
| FY2023 | Dec 31, 2023 | -12.6% | +45.2 |
| FY2022 | Dec 31, 2022 | -57.8% | +19.6 |
| FY2021 | Dec 31, 2021 | -77.4% | −83.2 |
| FY2020 | Dec 31, 2020 | 5.8% | +246.9 |
| FY2019 | Dec 31, 2019 | -241.0% | +5294.2 |
| FY2017 | Sep 30, 2017 | -5535.3% | +1445.8 |
| FY2016 | Sep 30, 2016 | -6981.1% | −3605.1 |
| FY2015 | Sep 30, 2015 | -3376.0% | −1405.0 |
| FY2014 | Sep 30, 2014 | -1971.0% | +6361.6 |
| FY2013 | Sep 30, 2013 | -8332.6% | −7143.9 |
| FY2011 | Sep 30, 2011 | -1188.7% | +91.5 |
| FY2010 | Sep 30, 2010 | -1280.2% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | 21.2% | +74.3 |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | -168.3% | −201.6 |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | -50.6% | −10.0 |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | -61.5% | +112.0 |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | -53.1% | −70.2 |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | 33.4% | +32.0 |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | -40.6% | −26.1 |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | -173.5% | −122.4 |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | 17.1% | +13.7 |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | 1.3% | +9.3 |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | -14.5% | +192.9 |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | -51.1% | −3.4 |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | 3.4% | +230.6 |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | -7.9% | +46.7 |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | -207.4% | −245.8 |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | -47.7% | +110.2 |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | -227.2% | −222.9 |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | -54.6% | −154.4 |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | 38.4% | +255.6 |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | -157.9% | −237.1 |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | -4.3% | +153.8 |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | 99.7% | +420.0 |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | -217.3% | +7571.6 |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | 79.2% | +3971.3 |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | -158.0% | +4393.7 |
| Q3 FY2019CQ3 2018 | Jun 30, 2019 | -320.3% | +6167.1 |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | -7788.8% | −2452.8 |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | -3892.1% | +2526.9 |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | -4551.7% | −3862.4 |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | -6487.4% | +7485.5 |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | -5336.0% | −348.6 |
| Q3 FY2016CQ2 2016 | Jun 30, 2016 | -6419.0% | −4687.3 |
| Q2 FY2016CQ1 2016 | Mar 31, 2016 | -689.4% | +2642.2 |
| Q1 FY2016CQ4 2015 | Dec 31, 2015 | -13972.9% | −10120.0 |
| Q4 FY2015CQ3 2015 | Sep 30, 2015 | -4987.5% | – |
| Q3 FY2015CQ2 2015 | Jun 30, 2015 | -1731.6% | – |
| Q2 FY2015CQ1 2015 | Mar 31, 2015 | -3331.6% | – |
| Q1 FY2015CQ4 2014 | Dec 31, 2014 | -3852.9% | – |
See a number that looks wrong?